
EU Approves AstraZeneca Mantle Cell Lymphoma Treatment
AstraZeneca announced on May 6, 2025 that its Calquence (acalabrutinib), a second-generation, selective inhibitor of Bruton’s tyrosine kinase (BTK), was approved in the European Union in combination with bendamustine and rituximab for treatment of adults …